To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC47636 | GLP-1R modulator C5 |
GLP-1R modulator C5 is an allosteric modulator enhancing GLP-1 binding to GLP-1R via a transmembrane site (EC50 1.59 ± 0.53 μM).
More description
|
|
| DC47634 | Glucocorticoids receptor agonist 1 |
Glucocorticoids receptor agonist 1 is a potent anti-inflammatory, arylpyrazole-based glucocorticoid receptor agonist that does not impair insulin secretion.
More description
|
|
| DC47633 | Glucocorticoids receptor agonist 2 |
Glucocorticoids receptor agonist 2 is a potent anti-inflammatory, arylpyrazole-based glucocorticoid receptor agonist that does not impair insulin secretion.
More description
|
|
| DC47631 | Ganoderlactone D |
Ganoderlactone D shows inhibitory effects of yeast α-Glucosidase with IC50 values of 41.7 μM.
More description
|
|
| DC47628 | GPR84 antagonist 1 |
GPR84 antagonist 1 is a high affinity and highly selective competitive antagonist of human GPR84.
More description
|
|
| DC47626 | HDAC/BET-IN-1 |
HDAC/BET-IN-1 displays submicromolar inhibitory activity against HDAC1 and 6 (IC50 = 0.163 μM and 0.067 μM), and BRD4 (Ki = 0.076 μM), and possess potent antileukemia activity.
More description
|
|
| DC47625 | Dihydrochlamydocin |
Dihydrochlamydocin is a Putative HDAC inhibitor.
More description
|
|
| DC47624 | HDAC1/2-IN-3 |
HDAC1/2-IN-3 is a HDAC1 and HDAC2 inhibitor with IC50 values 0-5 and 5-10 nM, respectively.
More description
|
|
| DC47623 | Dimethyl-bisphenol A |
Dimethyl-bisphenol A (DMBPA) is a potent HIF-1α inhibitor. Dimethyl-bisphenol A can decrease Vegfa mRNA expression.
More description
|
|
| DC47620 | Bomedemstat |
Bomedemstat (IMG-7289) is an oral and irreversible inhibitor of the epigenetically active lysine-specific demethylase 1 (LSD1) in mouse models of myeloproliferative neoplasms (MPNs). Bomedemstat can be used for the research of acute myelogenous leukemia (AML) and myelofibrosis (MF). Antineoplastic activity.
More description
|
|
| DC47617 | EED ligand 1 |
EED ligand 1 is a diverse, potent, and efficacious inhibitor that target the EED subunit of the polycomb repressive complex 2 (PRC2) methyltransferase.
More description
|
|
| DC47607 | Antiviral agent 9 |
Antiviral agent 9 reaches a single-digit picomolar EC50 value (0.006 nM) against HIV-1 and nearly 300-fold higher selectivity index (SI) compared to tenofovir alafenamide fumarate (TAF).
More description
|
|
| DC47605 | HIV-1 inhibitor-9 |
HIV-1 inhibitor-9 is found to be potent inhibitor against the wild-type (WT) HIV-1 strain or multiple NNRTI-resistant strains at low nanomolar levels.
More description
|
|
| DC47599 | Glabrescone C |
Glabrescone C possesses potent anti-inflammatory activity by directly bnding to IKKα/β.
More description
|
|
| DC47597 | IDO-IN-14 |
IDO-IN-14 is an IDO inhibitor with an IC50 value of 0.6928 nM.
More description
|
|
| DC47596 | IDO-IN-15 |
IDO-IN-15 is an IDO1 inhibitor (IC50 < 0.51 nM).
More description
|
|
| DC47592 | ITK/TRKA-IN-1 |
ITK/TRKA-IN-1 is a dual inhibitor of IL-2-inducible T-cell kinase (ITK) and tropomyosin receptor kinase A (TRKA) with an IC50 value of 1.0 nM and 96 % inhibition, respectively.
More description
|
|
| DC47587 | cIAP1 ligand 4 |
cIAP1 ligand 4 is a ligand for E3 ligase that can be used in the synthesis of PROTACs.
More description
|
|
| DC47577 | HPK1-IN-8 |
HPK1-IN-8 is an allosteric, inactive conformation-selective inhibitor of full-length HPK1.
More description
|
|
| DC47571 | Dolastatinol |
Dolastatinol is a synthetic analog of dolastatin 10 and low nanomolar inhibitor of tubulin polymerization.
More description
|
|
| DC47559 | Dihydroevocarpine |
Dihydroevocarpine induces cytotoxicity in acute myeloid leukemia via suppressing the mTORC1/2 activity.
More description
|
|
| DC47555 | CP-601932 |
CP-601932 ((1S,5R)-CP-601927) is a high-affinity partial agonist at α3β4 nAChR (EC50=~ 3 μM). CP-601932 has the same high-binding affinity at α3β4 (Ki=21 nM) as at α4β2 nAChRs (Ki=21 nM) and an order of magnitude lower affinity for α6 and α7 nAChR subtypes. CP-601932 selectively decreases ethanol but not sucrose consumption and operant self-administration following long-term exposure. CP-601932 readily penetrates the CNS.
More description
|
|
| DC47551 | IMD-vanillin |
IMD-vanillin is a novel imidazoquinolinone-NF-κB immunomodulator dimers.
More description
|
|
| DC47550 | HE 3286 |
HE3286, a synthetic derivative of the adrenal steroid β-AET, is an orally-active partially NF-κB inhibitor.
More description
|
|
| DC47549 | IMD-biphenylA |
IMD-biphenylA is a novel imidazoquinolinone-NF-κB immunomodulator dimer that improves the adjuvanticity of small molecule immune potentiators.
More description
|
|
| DC47548 | IMD-ferulic |
IMD-ferulic is a covalently linked NF-κB modulator that improves the adjuvanticity of small molecule immune potentiators.
More description
|
|
| DC47545 | IMD-biphenylC |
IMD-biphenylC is a novel imidazoquinolinone-NF-κB immunomodulator dimer that inhibits tumor proliferation while induces low systemic inflammation and reduces adjuvant toxicity.
More description
|
|
| DC47544 | IMD-catechol |
IMD-catechol is a novel imidazoquinolinone-NF-κB immunomodulator dimer that improves efficacy in a CT26 mouse colon carcinoma tumor model while eliciting minimal adjuvant toxicity.
More description
|
|
| DC47543 | FeTPPS |
FeTPPS, a 5,10,15,20-tetrakis (4-sulfonatophenyl) porphyrin iron III chloride peroxynitrite decomposition catalyst, possessed evident neuroprotective effects in a experimental model of spinal cord damage. FeTPPS acts as a peroxynitrite scavenger and anti-nitrating agent in vivo. FeTPPS reduces nitric oxide (NO) production and apoptosis process.
More description
|
|
| DC47528 | Compound 48/80 |
Compound 48/80 (Poly-p-methoxyphenethylmethylamine) is widely used in animal and tissue models as a "selective" mast cell activator. Compound 48/80 acts at the mast cell membrane to stimulate trimeric G-proteins and induces degranulation via phospholipase C and D pathways.
More description
|
|